Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Festa, A. Festa, A. Festa, R. D'Agostino, R. D’Agostino, R. D’Agostino, George Howard, George Howard, George Howard, L. Mykkänen, L. Mykkänen, L. Mykkänen, R. Tracy, R. Tracy, R. Tracy, S. Haffner, S. Haffner, S. Haffner (2000)
Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study.Kidney international, 58 4
J. Danesh, P. Whincup, M. Walker, L. Lennon, A. Thomson, P. Appleby, J. Gallimore, M. Pepys (2000)
Low grade inflammation and coronary heart disease: prospective study and updated meta-analysesBMJ : British Medical Journal, 321
P. Ridker, N. Rifai, M. Pfeffer, F. Sacks, L. Moye, S. Goldman, G. Flaker, E. Braunwald (1998)
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.Circulation, 98 9
H. Bøtker, J. Lassen, Flemming Hermansen, H. Wiggers, Peter Søgaard, Won Kim, Morten Bøttcher, L. Thuesen, Anders Pedersen (2001)
Electromechanical Mapping for Detection of Myocardial Viability in Patients With Ischemic CardiomyopathyCirculation: Journal of the American Heart Association, 103
D. Freeman, J. Norrie, M. Caslake, A. Gaw, I. Ford, G. Lowe, D. O’Reilly, C. Packard, N. Sattar (2002)
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.Diabetes, 51 5
J. Fernández-Real, W. Ricart (1999)
Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftinessDiabetologia, 42
S. Haffner, A. Greenberg, W. Weston, Hongzi Chen, K. Williams, M. Freed (2002)
Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes MellitusCirculation: Journal of the American Heart Association, 106
A. Pradhan, P. Ridker (2002)
Do atherosclerosis and type 2 diabetes share a common inflammatory basis?European heart journal, 23 11
V. Pasceri, J. Willerson, E. Yeh (2000)
Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial CellsCirculation: Journal of the American Heart Association, 102
W. Koenig, M. Sund, M. Fröhlich, H. Fischer, H. Löwel, A. Döring, W. Hutchinson, M. Pepys (1999)
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.Circulation, 99 2
B. Isomaa, P. Almgren, T. Tuomi, B. Forsén, Kaj Lahti, M. Nissen, M. Taskinen, L. Groop (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes care, 24 4
A. Festa, R. D'Agostino, R. Tracy, S. Haffner (2002)
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.Diabetes, 51 4
Metabolic Syndrome, and Risk of CV Events
S. Haffner, R. Valdez, H. Hazuda, B. Mitchell, P. Morales, M. Stern (1992)
Prospective analysis of the insulin-resistance syndrome (syndrome X).Diabetes, 41 6
C. Stehouwer, M. Gall, J. Twisk, E. Knudsen, J. Emeis, H. Parving (2002)
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.Diabetes, 51 4
A. Festa, R. D'Agostino, G. Howard, L. Mykkänen, R. Tracy, S. Haffner (2000)
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).Circulation, 102 1
P. Ridker, C. Hennekens, Julie Buring, N. Rifai (2000)
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.The New England journal of medicine, 342 12
M. Fröhlich, A. Imhof, G. Berg, W. Hutchinson, M. Pepys, H. Boeing, R. Muche, H. Brenner, W. Koenig (2000)
Association between C-reactive protein and features of the metabolic syndrome: a population-based study.Diabetes care, 23 12
K. Alberti, P. Zimmet (1998)
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 15
(2002)
American Heart Association Workshop on Inflammatory Markers, and Cardiovascular Disease: application to clinical and public health practice: Atlanta
J. Yudkin, C. Stehouwer, J. Emeis, S. Coppack (1999)
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?Arteriosclerosis, thrombosis, and vascular biology, 19 4
R. Tracy, R. Lemaitre, B. Psaty, D. Ives, R. Evans, M. Cushman, E. Meilahn, L. Kuller (1997)
Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project.Arteriosclerosis, thrombosis, and vascular biology, 17 6
Maurizio Trevisan, Jian Liu, Fadlalla Bahsas, A. Menotti (1998)
Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group.American journal of epidemiology, 148 10
P. Ridker, N. Rifai, L. Rose, J. Buring, N. Cook (2003)
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsObstetrical & Gynecological Survey, 58
J. Pickup, M. Crook (1998)
Is Type II diabetes mellitus a disease of the innate immune system?Diabetologia, 41
P. Ridker, M. Cushman, M. Stampfer, R. Tracy, C. Hennekens (1997)
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.The New England journal of medicine, 336 14
(2002)
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation, 106 25
A. Pradhan, J. Manson, N. Rifai, Julie Buring, P. Ridker (2001)
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.JAMA, 286 3
M. Mendall, P. Patel, L. Ballam, D. Strachan, T. Northfield (1996)
C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional studyBMJ, 312
E. Ford, W. Giles, W. Dietz (2002)
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.JAMA, 287 3
P. Ridker, M. Stampfer, N. Rifai (2001)
Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.JAMA, 285 19
P. Ridker, N. Rifai, M. Clearfield, J. Downs, S. Weis, J. Miles, A. Gotto (2001)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.The New England journal of medicine, 344 26
Clinical Investigation and Reports C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women Paul M Ridker, MD; Julie E. Buring, ScD; Nancy R. Cook, ScD; Nader Rifai, PhD Background—The metabolic syndrome describes a high-risk population having 3 or more of the following clinical characteristics: upper-body obesity, hypertriglyceridemia, low HDL, hypertension, and abnormal glucose. All of these attributes, however, are associated with increased levels of C-reactive protein (CRP). Methods and Results—We evaluated interrelationships between CRP, the metabolic syndrome, and incident cardiovas- cular events among 14 719 apparently healthy women who were followed up for an 8-year period for myocardial infarction, stroke, coronary revascularization, or cardiovascular death; 24% of the cohort had the metabolic syndrome at study entry. At baseline, median CRP levels for those with 0, 1, 2, 3, 4, or 5 characteristics of the metabolic syndrome were 0.68, 1.09, 1.93, 3.01, 3.88, and 5.75 mg/L, respectively (P 0.0001). Over the 8-year follow-up, trend cardiovascular event-free survival rates based on CRP levels above or below 3.0 mg/L were similar to survival rates based on having 3 or more characteristics of the metabolic syndrome. At all levels of severity
Circulation – Wolters Kluwer Health
Published: Jan 1, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.